MedWatch

Pharma-collaborations to secure success of Danish biotech company

It is collaborations with the big pharmaceutical companies, rather than investors, that are to secure operations in a Danish biotech company which makes it living updating existing medicine.

Foto: Colourbox

It is not investors but close collaborations with the established pharmaceutical industry that are going to ensure the continued operation of the Danish biotech company Ascendis Pharma, the company chairman tells Danish business daily Børsen, after Ascendis emerged from 2011 with a DKK 90.1 million deficit. The shareholders equity was DKK 125.7 million at the end of 2011 against 174.3 million at the end of 2010.

“We are backed by great investors, but we also know that we have to face facts. So our business strategy is meant to secure a balance between income and expenditure, so expenses aren’t financed by our shareholders but through collaborations,” chairman of the board Michael Wolff Jensen tells Børsen.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Her er de vigtigste nyheder fra MedWatch i uge 39

Et konsortium står til at overtage Ferrosan Medical Devices, der kan være klar til en børsnotering inden for en femårig tidshorisont. Derudover fortsætter kampen om medarbejderne i branchen, mens Novo Nordisk har indgået en ny aftale. Gik du glip af noget?

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier